PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Bannon’s War Room | Evening Edition | Recorded April 19, 2021 | Video: 48 Minutes 52 Seconds

Show Me

Washington Post’s Josh Rogin On Doctor Fauci’s Connections To the Origins of Covid & The Wuhan Lab | Video: 6 Minutes 20 Seconds

Show Me

Dr. Peter Navarro Discusses Dr. Fauci’s Sketchy Record on AIDS | Video: 2 Minutes 44 Seconds

Show Me

An Open Letter to Dr. Anthony Fauci | Originally Published May 31, 1988

Show Me

Who Is Sean Strubs? | Author Of “Body Counts: A Memoir of Activism, Sex, and Survival” by Sean Strub

Show Me

Whitewashing AIDS History | Dr. Anthony Fauci Is Rewriting History To Disguise His Shameful Role In Delaying Promotion of an AIDS Treatment That Would Have Prevented Tens of Thousands of Deaths In The First Years of the Epidemic.

Show Me

Henry Ford Doctors Pen An Open Letter On Hydroxychloroqine Study

Show Me

The Story Behind the First AIDS Drug

Show Me

Opinion: State Department Cables Warned of Safety Issues at Wuhan Lab Studying Bat Coronaviruses

Show Me

‘We Loved Each Other’: Fauci Recalls Larry Kramer, Friend and Nemesis

Show Me

The Claim That NIH Funded Gain of Function Experiments Is Just A ‘Conspiracy Theory’, Debunked | “Understanding the Risk of Bat Coronavirus Emergence” | NIH Project Number 2R01AI110964-06

Show Me

LISTEN: Police Dispatch Respond To Minneapolis Shooting After Maxine Waters Incited Riot, ’10 To 15 Shots’, ‘White SUV’

Show Me

Marjorie Taylor Greene to Introduce Resolution To Expel Maxine Waters As Democrats Continue To Incite Violence From Both Right and Left | Video: 1 Minute 45 Seconds

Show Me

The Nation Speaks (April 17): As Riots Return, What Lies Ahead; Supreme Court Under Review; Out of Afghanistan | Video: 59 Minutes 13 Seconds

Show Me

Andy Ngo: Antifa, BLM Gearing Up for More Violence as Riot Season Begins

Show Me

Arizona Senate Is Ready for Audit of Maricopa County’s 2020 Election Results to Begin – The Democrats Are In a Panic

Show Me

Video: Facts Matter (April 9): Experts Warn That Illegal Immigrants Are ‘Renting’ Children to Cross the Border

Show Me

EXCLUSIVE: Rep. Chip Roy To Introduce Legislation Making Cartels Terrorist Organizations

Show Me

Abbott Calls for Biden to Label Mexican Cartels as Terrorist Organizations as Texas Ranchers Fend off Criminals

Show Me

California forces Christian college employees to undergo gender identity training at odds with faith

Show Me

‘Completely anti-biblical’: Target selling devotional book that includes prayer to ‘hate white people’

Show Me

This past Easter Message from Joe Biden | “Day 73: While the Border Burns, Your New “Spiritual and Patriotic” Duty Is Here.”

Show Me

VIDEO: 200 Armed Riot Police Break Up Christian Church Service In Canada

Show Me

Pakistan: Further information: Health of death row prisoner in sharp decline: Shafqat and Shagufta

Show Me

Christian women face death penalty in Pakistan for removing sticker from Muslim coworker’s locker

Show Me

U.S. State Department’s Report on Nigerian Violence Leaves Out Jihad

Show Me

Opinion: Joe Biden must recognize Armenian genocides — the past and the present

Show Me

Commentary: Who Funds the Riotous American Left & Why?

Show Me

Liberty University sues Jerry Falwell Jr., seeking millions in damages

Show Me

Jason Whitlock Goes There: White Liberals Are ACTUAL Bigots

Show Me

Christian College Takes Biden to Court Over Trans Mandate

Show Me

UK Christian Leaders ‘Wholly Opposed’ to COVID-19 Vaccine Passports

Show Me

Argentinian Socialist Leader and Pro-Abortion Advocate Dies Days After Aborting Baby

Show Me

On The National Pulse Podcast with Raheem Kassam Discussing Bensman Book and Europe’s Terror Attacks

Show Me

Two Melbourne Men Face Terrorism Charges, Including for Links to ISIS

Show Me

Europe’s Migrant Crisis, Still Yielding Terror, Foretells The Effects Of Biden’s Border-Crossing Boom.

Show Me

Zion man gets more than 13 years in prison for conspiracy to support Islamic State, telling informant ‘I want to see blood flowing’

Show Me

College that censored Islamic terrorism quiz pays professor $155,000 to not sue

Show Me

Report: Mozambique Jihadists ‘Beheading, Skinning, Cutting off Limbs’

Show Me

Dozens Released From Gitmo Who Resumed Terrorism Remain At Large

Show Me